In this study, we report on a case in which upadacitinib, a JAK1-selective inhibitor, was used to manage a severe RA flare-up occurring in a patient receiving ICI therapy with the anti-PD-1 antibody pembrolizumab against stage IV lung squamous cell carcinoma. The gene discussed is PDCD1; the disease is rheumatoid arthritis.